The Treatment of Angina Pectoris with a New Beta-receptor Blocking Agent (H 56/28)

2009 ◽  
Vol 182 (3) ◽  
pp. 285-291 ◽  
Author(s):  
Per Björntorp
Keyword(s):  
Angina Pectoris ◽  
Blocking Agent ◽  
Receptor Blocking ◽  
Beta Receptor

Comparison of Nadolol, A New Long-Acting Beta-Receptor Blocking Agent, and Placebo in the Treatment of Stable Angina Pectoris

CHEST Journal ◽  
1981 ◽  
Vol 80 (4) ◽  
pp. 425-430 ◽  
Author(s):  
William Shapiro ◽  
Janet Park ◽  
Robert DiBianco ◽  
Steven N. Singh ◽  
Richard J. Katz ◽  
...  
Keyword(s):  
Angina Pectoris ◽  
Stable Angina ◽  
Blocking Agent ◽  
Stable Angina Pectoris ◽  
Receptor Blocking ◽  
Beta Receptor ◽  
Long Acting

scholarly journals EFFECT OF A NEW BETA-RECEPTOR BLOCKING AGENT, BFE-60 ON CARDIOVASCULAR SYSTEM

1973 ◽  
Vol 23 ◽  
pp. 35
Author(s):  
Yoichi Maruyama ◽  
Takafumi Ishihara ◽  
Ichiva Hiraki ◽  
Masayoshi Nozaki ◽  
Fumio Takenaka
Keyword(s):  
Cardiovascular System ◽  
Blocking Agent ◽  
Receptor Blocking ◽  
Beta Receptor

Generalized Convulsions in a Patient Receiving Ultrashort-Acting Beta-Blocker Infusion

1988 ◽  
Vol 22 (6) ◽  
pp. 484-485 ◽  
Author(s):  
Gopal Das ◽  
Janine C. Ferris
Keyword(s):  
Heart Disease ◽  
Beta Blocker ◽  
Blocking Agent ◽  
Literature Survey ◽  
Receptor Blocking ◽  
Blocking Agents ◽  
Beta Receptor ◽  
Generalized Seizures ◽  
Beta Blocking ◽  
Therapeutic Doses

Beta-receptor blocking agents are commonly used to treat patients with heart disease, and generalized seizures due to therapy with these agents are rare. All reported cases of seizures due to beta blocking agents have occurred only in those subjects who ingested large doses of the drugs. We observed generalized convulsions in a patient who was receiving therapeutic doses of an ultrashort-acting beta-blocking agent (esmolol hydrochloride) intravenously. A literature survey and possible mechanisms by which these agents induce seizures are presented.

A Double-Blind Trial of Penbutolol: A New Beta-Receptor Blocking Agent in the Treatment of Angina Pectoris

1976 ◽  
Vol 4 (6) ◽  
pp. 410-417 ◽  
Author(s):  
A K Agarwal ◽  
R C Ahuja ◽  
M Chandra ◽  
N N Gupta ◽  
M Hasan
Keyword(s):  
Angina Pectoris ◽  
Blocking Agent ◽  
Controlled Study ◽  
Double Blind Trial ◽  
Subjective Improvement ◽  
Double Blind ◽  
Dosage Range ◽  
Double Blind Placebo ◽  
Receptor Blocking ◽  
Blind Trial

A double-blind placebo controlled study of angina pectoris with Penbutolol was undertaken in parallel groups in fifty-two patients. The duration of the study was six weeks. The dosage range for Penbutolol was 8 mg to 50 mg per day. Six patients were dropped from the analysis. Seventeen patients (81%) in the Penbutolol series exhibited a 50% reduction in anginal attacks, NTG consumption and subjective improvement. Significant reduction in nitrite intake was observed. Effort tolerance was improved significantly in those receiving penbutolol. Penbutolol was well-tolerated.

Sign in / Sign up

Export Citation Format

Share Document